Recent Quotes
My Watchlist
Indicators
Local Stocks
Buffalo Local Index
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by Theratechnologies

< Previous 1 2 Next >
Theratechnologies IDWeek Presentations Highlight the Impact of Excess Visceral Abdominal Fat (EVAF) on Cardiovascular Disease (CVD) Risk in People with HIV
From Theratechnologies
Via GlobeNewswire
Tickers THTX TSX:TH
Theratechnologies Unveils Study Design and Baseline Characteristics of PROMISE-US Trial of Ibalizumab in Heavily Treatment-Experienced People with HIV and Multidrug Resistance
From Theratechnologies
Via GlobeNewswire
Tickers THTX TSX:TH
Theratechnologies Reports Strong Financial Results and Announces Positive Net Income for Third Quarter 2024
From Theratechnologies
Via GlobeNewswire
Tickers THTX TSX:TH
Theratechnologies to Present Data at IDWeek 2024 Highlighting Advances in Treatment and Management of Complications in People with HIV
From Theratechnologies
Via GlobeNewswire
Tickers THTX TSX:TH
Theratechnologies to Announce Third Quarter 2024 Financial Results and Provide Business Update
From Theratechnologies
Via GlobeNewswire
Tickers THTX TSX:TH
Theratechnologies Announces a Risk of a Temporary Supply Disruption for EGRIFTA SV® in Early 2025
From Theratechnologies
Via GlobeNewswire
Tickers THTX TSX:TH
Theratechnologies to Present at Upcoming Investor Conferences in September
From Theratechnologies
Via GlobeNewswire
Tickers THTX TSX:TH
Theratechnologies Reports Financial Results and Announces Positive Net Income for Second Quarter 2024
From Theratechnologies
Via GlobeNewswire
Tickers THTX TSX:TH
Theratechnologies to Announce Second Quarter 2024 Financial Results and Provide Business Update
From Theratechnologies
Via GlobeNewswire
Tickers THTX TSX:TH
Theratechnologies’ Sudocetaxel Zendusortide ASCO 2024 Presentation Demonstrates Signs of Long-Term Efficacy and Manageable Safety Profile in Patients with Solid Tumors
From Theratechnologies
Via GlobeNewswire
Tickers THTX TSX:TH
Theratechnologies Reports on its Annual Meeting of Shareholders
From Theratechnologies
Via GlobeNewswire
Tickers THTX TSX:TH
Theratechnologies to Present Long-Term Efficacy, Safety and Pharmacokinetic Data on Use of TH1902 (sudocetaxel zendusortide) in Solid Tumors at 2024 ASCO Meeting
From Theratechnologies
Via GlobeNewswire
Tickers THTX TSX:TH
Theratechnologies Announces Mailing of Management Proxy Circular in Connection with its Annual Meeting of Shareholders
From Theratechnologies
Via GlobeNewswire
Tickers THTX TSX:TH
Theratechnologies to Present at the 2024 Bloom Burton & Co. Healthcare Investor Conference
From Theratechnologies
Via GlobeNewswire
Tickers THTX TSX:TH
Theratechnologies Reports Financial Results and Provides Business Update for First Quarter 2024
From Theratechnologies
Via GlobeNewswire
Tickers THTX TSX:TH
Theratechnologies Preclinical Data Presentation at AACR 2024 Highlights Versatility and Flexibility of SORT1+ Technology™ Oncology Platform
From Theratechnologies
Via GlobeNewswire
Tickers THTX TSX:TH
Theratechnologies Appoints Elina Tea to its Board of Directors
From Theratechnologies
Via GlobeNewswire
Tickers THTX TSX:TH
Theratechnologies to Announce First Quarter 2024 Financial Results and Provide Business Update
From Theratechnologies
Via GlobeNewswire
Tickers THTX TSX:TH
Theratechnologies to Present Preclinical Data at AACR on Multiple PDCs Showcasing Potential of SORT1+Technology™ Platform
From Theratechnologies
Via GlobeNewswire
Tickers THTX TSX:TH
Theratechnologies Announces Update on its Preclinical Oncology Research Program
From Theratechnologies
Via GlobeNewswire
Tickers THTX TSX:TH
Theratechnologies Appoints Jordan Zwick to its Board of Directors
From Theratechnologies
Via GlobeNewswire
Tickers THTX TSX:TH
Theratechnologies Initiates Increased Dose Level in Phase 1 Clinical Trial of Sudocetaxel Zendusortide in Advanced Ovarian Cancer
From Theratechnologies
Via GlobeNewswire
Tickers THTX TSX:TH
Theratechnologies Announces the Resignation of One of Its Directors, Mr. Alain Trudeau
From Theratechnologies
Via GlobeNewswire
Tickers THTX TSX:TH
Theratechnologies Receives Refusal to File Letter for Trogarzo® Intramuscular Method of Administration sBLA from FDA
From Theratechnologies
Via GlobeNewswire
Tickers THTX TSX:TH
Theratechnologies Reports Financial Results for the Fourth Quarter and Full Year of Fiscal 2023 and Provides 2024 Guidance
From Theratechnologies
Via GlobeNewswire
Tickers THTX TSX:TH
Theratechnologies Announces Publication in Frontiers in Immunology that Deepens Understanding of Sudocetaxel Zendusortide (TH1902) Molecular Mechanism of Action
From Theratechnologies
Via GlobeNewswire
Tickers THTX TSX:TH
Theratechnologies Completes Enrollment of First Six Patients in Updated Phase 1 Clinical Trial of Sudocetaxel Zendusortide in Advanced Ovarian Cancer
From Theratechnologies
Via GlobeNewswire
Tickers THTX TSX:TH
Theratechnologies to Announce Fourth Quarter and Full Year 2023 Financial Results and Provide Business Update
From Theratechnologies
Via GlobeNewswire
Tickers THTX TSX:TH
Theratechnologies Receives Complete Response Letter (CRL) from the FDA for the F8 Formulation of Tesamorelin sBLA
From Theratechnologies
Via GlobeNewswire
Tickers THTX TSX:TH
Theratechnologies Receives Update from FDA on Tesamorelin F8 Supplemental Biologic License Application
From Theratechnologies
Via GlobeNewswire
Tickers THTX TSX:TH
< Previous 1 2 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.